A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

Inclusion Criteria: Pediatric patients aged 3 months to less than 12 years at the time of Pradaxa Pellets initiation * Written informed consent from parents/care givers and patient assent if age appropriate * Initiation of Pradaxa Pellets administration either as initial or subsequent therapy: * Treatment of VTE * Treatment to reduce the risk of recurrence of VTE Exclusion Criteria: * Participation in any randomized clinical trial or use of investigational product, participation in any other observational study is not an exclusion * Any contraindications to Pradaxa Pellets according to the US Prescribing Information. * Previous participation in this study.